company background image
0AL logo

Agile Therapeutics DB:0AL Stock Report

Last Price

€7.24

Market Cap

€8.1m

7D

0%

1Y

-80.9%

Updated

10 Jul, 2023

Data

Company Financials +

0AL Stock Overview

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.

0AL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Agile Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agile Therapeutics
Historical stock prices
Current Share PriceUS$7.24
52 Week HighUS$38.00
52 Week LowUS$7.24
Beta1.13
1 Month Change0%
3 Month Change-23.09%
1 Year Change-80.94%
3 Year Change-99.83%
5 Year Change-99.12%
Change since IPO-99.92%

Recent News & Updates

Recent updates

Shareholder Returns

0ALDE PharmaceuticalsDE Market
7D0%2.3%1.9%
1Y-80.9%-25.9%7.3%

Return vs Industry: 0AL underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: 0AL underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 0AL's price volatile compared to industry and market?
0AL volatility
0AL Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0AL's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0AL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199722Al Altomarihttps://www.agiletherapeutics.com

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Agile Therapeutics, Inc. Fundamentals Summary

How do Agile Therapeutics's earnings and revenue compare to its market cap?
0AL fundamental statistics
Market cap€8.07m
Earnings (TTM)-€18.62m
Revenue (TTM)€11.80m

0.7x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0AL income statement (TTM)
RevenueUS$12.94m
Cost of RevenueUS$7.31m
Gross ProfitUS$5.62m
Other ExpensesUS$26.04m
Earnings-US$20.42m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.97
Gross Margin43.48%
Net Profit Margin-157.83%
Debt/Equity Ratio-16.0%

How did 0AL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.